These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9586075

  • 1. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M, Kuwabara T, Taira K.
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K.
    Nucleic Acids Res; 1997 Aug 01; 25(15):3074-81. PubMed ID: 9224607
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activities of tRNA-embedded dimeric minizymes.
    Kuwabara T, Warashina M, Nakayama A, Ohkawa J, Taira K.
    Nucleic Acids Symp Ser; 1997 Aug 01; (37):307-8. PubMed ID: 9586122
    [Abstract] [Full Text] [Related]

  • 5. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R, Haas R, Sczakiel G.
    J Mol Biol; 1996 Jun 21; 259(4):632-44. PubMed ID: 8683570
    [Abstract] [Full Text] [Related]

  • 6. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H, Mills K, Gibson I.
    Leukemia; 1996 Jun 21; 10(6):1054-64. PubMed ID: 8667643
    [Abstract] [Full Text] [Related]

  • 7. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P, Wright LA, Milliken S, Biggs JC.
    Exp Hematol; 1995 Aug 21; 23(9):986-9. PubMed ID: 7543419
    [Abstract] [Full Text] [Related]

  • 8. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ, Yoon K, Moelling K, Coney LR.
    Nucleic Acids Res; 1994 Feb 11; 22(3):301-7. PubMed ID: 8127665
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 11; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 10. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec 11; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 11. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 11; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 12. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W.
    Klin Padiatr; 1995 Jan 11; 207(4):222-4. PubMed ID: 7564157
    [Abstract] [Full Text] [Related]

  • 13. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH, Wu SC, Chen WS, Yen CC, Yang MH, Tsai YC, Chen PM.
    Biochem Biophys Res Commun; 2004 Jun 04; 318(3):764-72. PubMed ID: 15144904
    [Abstract] [Full Text] [Related]

  • 14. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M, Kuwabara T, Warashina M, Nakayama A, Taira K.
    FEBS Lett; 1999 Nov 12; 461(1-2):77-85. PubMed ID: 10561500
    [Abstract] [Full Text] [Related]

  • 15. [Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report].
    Hashimoto S, Hiyoshi M, Hino M, Yamane T, Ota T, Koh KR, Tagawa S, Tatsumi N.
    Rinsho Ketsueki; 1997 Jan 12; 38(1):72-4. PubMed ID: 9028165
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS.
    Hum Gene Ther; 1999 Nov 20; 10(17):2847-57. PubMed ID: 10584930
    [Abstract] [Full Text] [Related]

  • 17. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
    Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E, de Vivo A, Mianulli A, Saglio G, Tura S.
    Haematologica; 2000 Jan 20; 85(1):40-6. PubMed ID: 10629590
    [Abstract] [Full Text] [Related]

  • 18. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK, Nabissa PM, Reddy EP.
    Oncogene; 1993 Nov 20; 8(11):3183-8. PubMed ID: 8414522
    [Abstract] [Full Text] [Related]

  • 19. Design and kinetic analysis of hammerhead ribozyme and DNAzyme that specifically cleave TEL-AML1 chimeric mRNA.
    Choi WH, Choi BR, Kim JH, Yeo WS, Oh S, Kim DE.
    Biochem Biophys Res Commun; 2008 Sep 12; 374(1):169-74. PubMed ID: 18627769
    [Abstract] [Full Text] [Related]

  • 20. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T, Hamada M, Warashina M, Taira K.
    Biomacromolecules; 2001 Sep 12; 2(3):788-99. PubMed ID: 11710033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.